A comparison between the adverse event profiles of patients receiving palbociclib and abemaciclib: analysis of two real-world databases.

This study is the first to show comprehensively the disparities in the AE profiles of palbociclib and abemaciclib. The findings highlight the importance of considering these differences when selecting a suitable CDK4/6 inhibitor to ensure safe and favourable outcomes for patients with breast cancer.